FDA Gives Thumbs Down To Amgen’s Film Noir Aranesp Promo
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen’s direct mailer featuring the image of a man in free fall misleading suggests Aranesp is useful in a broader patient population than it is indicated for, agency says.
You may also be interested in...
Amgen’s Neulasta Ad Indirectly Targeting Biosimilars Draws US FDA Rebuke
Animated banner ad claiming administration of Neulasta with Amgen’s Onpro on-body injector has less risk of febrile neutropenia than administration via prefilled syringe draws untitled letter and a rare press release. FDA says claims could undermine confidence in biosimilar pegfilgrastim products.
FDA Enforcement Letters On Rx Drug Promotions Plummet In 2013
OPDP Director Tom Abrams cautions against reading into the “snapshot.”
Amgen’s Aranesp v. Procrit Promotional Claims Result In Off-Label Guilty Plea
Amgen pled guilty to marketing Aranesp off-label as part of a global settlement with the government; the final agreement, expected to be approved on Dec. 19, could involve marketing practices of Enbrel and six other drugs.